S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NYSE:BIO - Bio-Rad Laboratories Stock Price, Forecast & News

$349.11
+26.70 (+8.28 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$322.14
Now: $349.11
$351.45
50-Day Range
$320.01
MA: $367.11
$409.07
52-Week Range
$281.66
Now: $349.11
$413.02
Volume193,676 shs
Average Volume214,347 shs
Market Capitalization$10.45 billion
P/E Ratio6.00
Dividend YieldN/A
Beta1.06
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Read More
Bio-Rad Laboratories logo

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP09057220
Phone510-724-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.31 billion
Cash Flow$7.71 per share
Book Value$192.32 per share

Profitability

Net Income$1.76 billion

Miscellaneous

Employees8,120
Market Cap$10.45 billion
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.


Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

How has Bio-Rad Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Bio-Rad Laboratories' stock was trading at $345.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BIO stock has increased by 1.0% and is now trading at $349.11. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bio-Rad Laboratories?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bio-Rad Laboratories.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Bio-Rad Laboratories.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) released its earnings results on Thursday, February, 13th. The medical research company reported $2.32 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $2.44 by $0.12. The medical research company earned $624.43 million during the quarter, compared to analyst estimates of $636.50 million. Bio-Rad Laboratories had a net margin of 76.08% and a return on equity of 4.06%. View Bio-Rad Laboratories' earnings history.

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.416-2.433 billion, compared to the consensus revenue estimate of $2.42 billion.

What price target have analysts set for BIO?

5 brokerages have issued 12 month target prices for Bio-Rad Laboratories' stock. Their forecasts range from $375.00 to $430.00. On average, they anticipate Bio-Rad Laboratories' stock price to reach $403.00 in the next year. This suggests a possible upside of 15.4% from the stock's current price. View analysts' price targets for Bio-Rad Laboratories.

Has Bio-Rad Laboratories been receiving favorable news coverage?

Media coverage about BIO stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bio-Rad Laboratories earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutBio-Rad Laboratories.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 664,100 shares, an increase of 5.3% from the February 27th total of 630,500 shares. Based on an average daily volume of 201,200 shares, the days-to-cover ratio is presently 3.3 days. Currently, 3.1% of the shares of the company are sold short. View Bio-Rad Laboratories' Current Options Chain.

Who are some of Bio-Rad Laboratories' key competitors?

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), First Solar (FSLR), AbbVie (ABBV), Dynavax Technologies (DVAX), ImmunoGen (IMGN), Celgene (CELG) and Exelixis (EXEL).

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the following people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 69)
  • Ms. Christine A. Tsingos, Exec. Officer (Age 60)
  • Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 63)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 57)
  • Ms. Annette Tumolo, Exec. VP & Pres of Life Science Group (Age 64)

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (2.19%), FMR LLC (2.15%), Westfield Capital Management Co. LP (1.54%), UBS Asset Management Americas Inc. (1.47%), Alliancebernstein L.P. (1.26%) and AQR Capital Management LLC (1.07%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Christine A Tsingos, James R Stark, John Hertia, Michael Crowley and Timothy S Ernst. View institutional ownership trends for Bio-Rad Laboratories.

Which major investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including Levin Easterly Partners LLC, Point72 Asset Management L.P., Russell Investments Group Ltd., Marshall Wace LLP, Royce & Associates LP, Franklin Resources Inc., Franklin Resources Inc., and Nuveen Asset Management LLC. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include James R Stark, John Hertia, Michael Crowley, and Timothy S Ernst. View insider buying and selling activity for Bio-Rad Laboratories.

Which major investors are buying Bio-Rad Laboratories stock?

BIO stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Pictet Asset Management Ltd., State Street Corp, FMR LLC, AQR Capital Management LLC, Sumitomo Mitsui Trust Holdings Inc., Goldman Sachs Group Inc., and Westfield Capital Management Co. LP. View insider buying and selling activity for Bio-Rad Laboratories.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $349.11.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $10.45 billion and generates $2.31 billion in revenue each year. The medical research company earns $1.76 billion in net income (profit) each year or $7.06 on an earnings per share basis. Bio-Rad Laboratories employs 8,120 workers across the globe. View additional information about Bio-Rad Laboratories.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is http://www.bio-rad.com/.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


MarketBeat Community Rating for Bio-Rad Laboratories (NYSE BIO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  323 (Vote Outperform)
Underperform Votes:  346 (Vote Underperform)
Total Votes:  669
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe BIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel